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There is accumulating evidence for a link between circadian clock disruption and cancer progression. In 
this study, the circadian clock was investigated in cervical and oesophageal cancers, to determine
whether it is disrupted in these cancer types. Oncomine data-mining revealed simultaneous
downregulation of multiple members of the circadian clock gene family in cervical cancer and
oesophageal cancer patient tissue compared to matched normal epithelium. Real-time RT-PCR analysis
confirmed significant downregulation of Clock, Per1, Per2, Per3, Cry1, Cry2 and Rev-erbα and RORα in
oesophageal tumour tissue. In cell line models, expression of several circadian clock gene family
members was significantly decreased in transformed and cancer cells compared to non-cancer controls, 
and protein levels were also dysregulated. These effects were mediated at least in part by methylation, 
where promoter regions of the Clock, Cry1 and RORα genes were found to be methylated in cancer cells. 
Overexpression of Clock and Per2 in cancer cell lines negatively affected cell proliferation, and activation
of RORα and Rev-erbα using agonists resulted in cancer cell death, while having a lesser effect on normal
epithelial cells. Despite dysregulated circadian clock gene expression, cervical and oesophageal cancer
cells maintain functional circadian oscillations after synchronisation with Dexamethasone, as revealed
using real-time bioluminescence imaging, suggesting that their circadian clock mechanisms are still
intact. Together, this study is a first to describe dysregulated circadian clock gene expression in cervical
and oesophageal cancer, although cells maintain a functional circadian rhythm. Elucidating differences
in circadian clock functioning in normal and cancer cells could yield important insights into the timing of 






   
    
  
    
     
  
 
    
       
   
   
 
   
 
  
   
   
  
    
       
   
Introduction
The circadian clock aligns metabolic and physiological processes, at cellular and systemic levels, to the 
external light and dark 24 hour cycle. At the molecular level, the circadian clock comprises a core set of
rhythmically expressed genes and gene products, Bmal1, Clock, Cryptochrome (Cry), Period (Per), Rev-
erb and ROR, that drive rhythmic expression of clock-controlled genes to generate overt circadian
rhythms 1. Clock and Bmal1 proteins heterodimerise and activate the expression of Cry and Per genes,
which once translated in the cytoplasm repress Clock/Bmal1 activity to inhibit their own transcription 1. 
Bmal1 levels are further controlled by negative and positive regulatory transcription factors, Rev-erbα/β 
and RORα 1. All nucleated cells harbour a circadian clock mechanism and express circadian clock genes 2. 
The suprachiasmatic nucleus (SCN) is the master clock in the brain which receives light signals via the
retino-hypothalamic tract and generates neural and hormonal signals accordingly 2. This is turn
synchronises peripheral clocks, which are those molecular clock networks expressed in all non-SCN cell
types. Up to 40 % of the genome is regulated in a circadian fashion, highlighting the crucial role of the
circadian clock in cell biology 3. Its dysregulation is implicated in several disease states, including cancer. 
Circadian disruption has been correlated with increased cancer risk and progression. This correlation has 
been evident in shift workers and the International Agency for Research on Cancer (IARC) classified
shiftwork that results in circadian disruption as a probable carcinogen (group 2A carcinogen) 4. With
recent epidemiological data suggesting that more than 80 % of the population may be living a lifestyle of 
chronic circadian disruption, this has widespread implications 5. In mouse studies, disruption of the light
cycle accelerates tumourigenesis 6 and meal timing inhibits cancer growth by approximately 40 %, as




     
     
   
  
         
 
 
   
  
 
    
     
     
    
   
  
     
      
     
 
     
     
      
commonly display a disrupted circadian rhythm or exhibit deregulated circadian clock gene expression 8, 
where for example loss of circadian clock gene expression has been correlated with poor prognosis in 
various cancer types 9,10,11,12. It has recently been shown that tumour hypoxia aggravates the extent of
circadian dysregulation 13. Furthermore, a link between metabolic perturbations of cancer cells and 
circadian clock disruption has been described 14. These studies highlight how the circadian clock is
entwined in important cellular processes implicated in cancer development.
While disruptions in the circadian clock have been described in certain cancers, there are no 
documented reports to date on the circadian machinery of cervical cancer or oesophageal cancer cells,
and with these cancer types being prevalent in the developing world they require further investigation.
Cervical cancer was classified as the fourth most common cancer among women worldwide in 2018, and
the second most common cancer among women in countries with a low human development index
(HDI) (GLOBOCAN 2018, IARC) 15. Oesophageal cancer was classified as the seventh most common
cancer among men worldwide in 2018, and the sixth most common cancer among men and seventh
among women in countries with a low HDI 15. Knowledge of circadian clock functioning in these cancer
types could provide important information to benefit diagnosis and treatment. In particular, with many
drug targets and drug metabolising enzymes expression in a circadian fashion, knowledge of the
circadian rhythm exhibited by cancer cells can inform when to optimally administer chemotherapy,
enhancing its efficacy and minimising toxicity.
In this study we show that expression of multiple circadian clock genes is downregulated in cervical and
oesophageal cancer cells. These cells however, maintain functional circadian oscillations. Furthermore,




        
   
 
  
effect on cancer biology. It has been reported that circadian clock genes are potential “druggable”
targets, due to their dysregulation in cancer cells 5. Our study supports further investigation into the







    
         
    
   
   
      
     
   
   
 
     
   
    
   
   
   
    
 
Methods
Cell lines and cell culture
Human primary and immortalized retinal epithelial cell lines, ARPE19 and hTERT-RPE-1, respectively,
were cultured in DMEM:F12 (Gibco) supplemented with 10 % fetal bovine serum (FBS, Gibco) and
penicillin and streptomycin. hTERT-RPE-1 media was supplemented with 0.01 mg/ml Hygromycin B.
Human fibroblasts (WI38 and SVWI38), cervical cancer cell lines (HeLa, CaSki and ME180), oesophageal 
cancer cell lines (WHCO1, WHCO5 and KYSE30), and osteosarcoma cell line (U2OS) were maintained in 
DMEM (Gibco) supplemented with 10 % fetal bovine serum and penicillin and streptomycin. All cells
except U2OS cells, which were kindly provided by Prof. J. Hapgood, University of Cape Town, were 
obtained from the ATCC. Cells were maintained in a humidified incubator at 37°C and in 5 % carbon 
dioxide. Cancer cell lines were authenticated by DNA profiling using the Cell ID system (Promega). 
Stable cell lines were generated using the Tol2 transposon system as described by Yagita et al., 2010 16. 
The Per2 promoter fused to destabilized luciferase (Per2-dLuc) was kindly provided by Prof. K. Yagita
(Kyoto Prefectural University of Medicine, Japan). The Bmal1-dLuc construct was generated by excising
the Bmal1 promoter-luciferase construct from the pGL4.27 plasmid, kindly provided by Dr J. Hogenesch
(University of Pennsylvania, USA) 17, and inserting it into the Tol2 plasmid. Cells were transfected using
Genecellin (Celtic Diagnostics) and stable Per2-dLuc- or Bmal1-dLuc-expressing cells selected for in




      




    
    
   
  
     
  






     
    
    
    
 
    
Cells were treated with RORα agonist, SR1078 (Merck), Rev-erbα agonist, SR9011 (Sigma), and the
methylation inhibitor, 5-aza-2-deoxycytidine (Sigma), dissolved in DMSO. Drug stocks were prepared at
concentrations of 5 mM, 4.175 mM and 10 mM, respectively, and stored at -20°C. 
Clinical specimens
24 pairs of freshly frozen normal oesophageal epithelial and oesophageal cancer samples, and 8 freshly 
frozen normal cervical epithelial and 16 cervical cancer samples, were obtained from patients at Groote 
Schuur and Tygerberg hospitals and RNA extracted. Time of tissue collection was important in a study
examining the circadian clock: all cervical specimens (normal and cancer) were collected during the 
morning (between 8 am and midday) so at an approximately equivalent time of day, and since
oesophageal specimens comprised normal and cancer epithelial tissue, matched normal and cancer
samples were from the same time of day. This study was authorized by the University of Cape Town
Research Ethics Committee (REC REF: 153/2004 and 040/2005), and written informed consents were
provided by all patients for using their biopsy tissue samples.
Plasmids
Overexpression plasmids were obtained as follows: myc-tagged mPer2 (pCS2+mt-6myc-mPER2) was
kindly provided by Prof. David Virshup (Duke-MED Medical School, Singapore) 18, flag-tagged mClock
(pCMV10/3Xflag-Clock) was purchased from Addgene and a kind gift from Joseph Takahashi (Addgene
plasmid #47334) 19, flag-, myc- and his-tagged hCry1 in pcDNA4 (pfmh-hCry1) was purchased from
Addgene and a kind gift from Aziz Sancar (Addgene plasmid #25843), and Venus-tagged mBmal1
(pcDNA3.1-Venus-mBmal1) was kindly provided by Prof. Kyungjin Kim (University of Pennsylvania School 








    
     
  
     
 












   
  
their respective plasmids, and religation using the Quick Blunting and Quick Ligation kits (New England
Biolabs). 
RNA extraction and reverse transcription quantitative PCR (RT-qPCR) 
Total RNA was extracted from patient tissue and cultured cell lines (2 hours after Dexamethasone 
synchronisation) using Qiazol Reagent (Qiagen) according to the manufacturer’s instructions. RNA was
reverse-transcribed to cDNA with ImPromII reverse transcriptase (Promega). Quantitative PCR reactions
were performed using the Kapa Fast SYBR Green qPCR reagent (Kapa Biosystems), using the following
primers: Clock forward, 5’-GTAGCTTGTGGGGCAGTCAT-3′ and reverse, 5’-TGGAGCAACCTAGAAGTCTGT-
3′; Bmal1 forward, 5’-ATTCTTGGTGAGAACCCCCAC-3′ and reverse, 5’-TGTAGTGTTTACAGCGGCCA-3′, Cry1
forward, 5’-GCAGTTGCTTGCTTCCTGAC-3′ and reverse, 5’-GACAGGCAAATAACGCCTGA-3′, Cry2 forward, 
5’-CCTGAGACTGCAGAGCCCTT-3’ and reverse, 5’-CTGGCGTGCTACAGGTACTC-3’, Per1 forward, 5’-
AGGATCCCATTTGGCTGCTC-3′ and reverse, 5’-TCCACACAGGCCATCACAT-3′, Per2 forward, 5’-
ATCGACGTGGCAGAATGTGT-3′ and reverse, 5’-TCTCTTCCAAGCACCACCTG-3′, Per3 forward, 5’-
AGACACCTGAGCGCATTCTC-3’ and reverse, 5’-GTGACACAGGCTTGAATGTCG-3’, RORα forward, 5’-
AGCAGATCGCTCATGGCTG-3′ and reverse, 5’-GAAGTCGCACAATGTCTGGG-3′, RORβ forward, 5’-
CTGATATCTCCAGACCGAGCC-3’ and reverse, 5’-CAAACTGCCGTGATGGTTGG-3’, RORƴ forward, 5’-
GAAGTGACTGGCTACCAGAGG-3’ and reverse, 5’-CACTTCCATTGCTCCTGCTTTG-3’, Rev-erbα forward, 5’-
CTTTGAGGTGCTGATGGTGCG-3′ and reverse, 5’-CACCGAAGCGGAATTCTCCA-3′, Rev-erbβ forward, 5’-
GGAGGAAGAATGCATCTGGTTTG-3’ and reverse, 5’-GAACCCAGGAATACGCTTTGC-3’, GAPDH forward, 5’-
GGCTCTCCAGAACATCATCC-3’ and reverse, 5’-GCCTGCTTCACCACCTTC-3’, β-glucuronidase forward, 5’-
CTCATTTGGAATTTTGCCGATT-3’ and reverse, 5’-CCGAGTGAAGATCCCCTTTTTA-3’ and Cyclophilin D




    




       
     
  
       
   
     
     
    
      
      




   
   
 
applied as the endogenous controls for normalization, and the 2-△△CT was used to calculate the 
relative mRNA expression 21.
Western blot analysis
Protein was extracted from cells 2 hours after synchronisation with Dexamethasone, using RIPA lysis 
buffer and the Bicinchoninic acid (BCA) assay kit (Pierce) used to determine protein concentration. A
total of 20μg protein was separated by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and then
transferred onto nitrocellulose membranes (Millipore). After transfer, the membrane was blocked in 5% 
skimmed milk for 1 h and then incubated with primary anti-Clock (1:2000; Pierce #PA1-520), anti-Bmal1
(1:2000; Abcam #ab93806), anti-Cry1 (1:1000; Santa Cruz Biotechnology #sc-33177), anti-Per2 (1:1000; 
Abcam #ab179813), anti-RORα (1:750; Abcam #ab70061), anti-Rev-erbα (1:500, Millipore #AB10130), 
or anti-p38 (1:5000, Sigma #M0800) antibody overnight at 4°C, followed by species-matched secondary
antibodies for 1 h at room temperature. Finally, protein bands were visualized using Lumiglo detection
reagent (Thermofisher). For Parp-1 cleavage analysis, protein was harvested from cells and cell floaters 
72 hours after treatment with SR9011 or SR1078 using RIPA lyisis buffer and Western blot analysis
performed, as above, using anti-Parp-1 (1:500; Santa Cruz Biotechnology #sc-7150) antibody overnight 
at 4°C. 
Methylation-specific PCR
Bisulfite treatment of genomic DNA was carried out using the EpiTect Fast LyseAll Bisulfite Kit (Qiagen),
according to the manufacturer’s instructions. Bisulfite-modified DNA was then amplified by PCR using 




       
         
   
      
  
  
   
  
    
     
    
    










and according to Davidovic et al. (2014) 22 (as listed in Table 1). PCR was carried out using 200 nM each 
primer, 200 µM dNTPs, 1.5 mM MgCl2 1.25 U GoTaq G2 Flexi DNA polymerase (Promega) and 100 ng 
bisulfite-converted DNA. Cycling conditions were: 95°C for 2 minutes, followed by 40 cycles of 95°C for
30 seconds, 52°C or 55°C (for unmethylated or methylated primer reactions, respectively), and 72°C for
30 seconds, followed by a final elongation step of 72°C for 5 minutes. The PCR products were visualized
by 1.5 % agarose gel electrophoresis. CpG methylase (SssI)-treated sodium bisulfite-modified genomic
DNA was used as a positive control for methylation-specific primers. To determine the effect of 5-aza-2-
deoxycytidine on circadian clock gene promoter methylation, cells were treated with varying
concentrations of 5-aza-2-deoxycytidine every day for 3 days, and the next day DNA harvested, and
bisulfite converted. DNA amplification was then performed by real-time PCR, using the Kapa Fast SYBR
Green qPCR reagent (Kapa Biosystems) and 250 nM each methylation-specific primer. PCR amplification
was stopped before fluorescence generated from untreated cancer cell lines had reached saturation (or
the “plateau effect”); that is at 35 cycles for Clock and 28 cycles for RORα and Cry1. PCR products were
visualized by 1.5 % agarose gel electrophoresis.
MTT cell proliferation assays
5000 cells/well were plated in 96-well plates and the following day either transfected with
overexpression plasmids, using Genecellin (Celtic Diagnostics), or treated with RORα/Rev-erbα agonists. 
Proliferation was assessed 3 to 4 days after treatment or transfection, respectively by addition of MTT in
PBS at 5 mg/ml. After incubation at 37°C for 4 hours, MTT solvent was added and absorbance measured





       
 




     
    






    
   
    
  
    
     
 
Trypan blue assays
Cells were plated in 24-well plates and treated with varying concentrations of RORα/Rev-erbα agonists
for 72 hours. Following treatment, cell floaters and adherent cells were collected by trypsinization,
stained using 0.4 % Trypan blue stain, and counted using a haemacytometer. Dead cells were counted as
those cells that had stained blue, whereas live cells were those that had excluded the stain.
Caspase-Glo 3/7 assay
Cells were plated in 96-well plates and treated with RORα/Rev-erbα agonists for 72 hours, whereafter
the Caspase-Glo 3/7 assay (Promega) was performed, according to the manufacturer’s instructions.
Luminescence was measured using the Veritas microplate luminometer (Promega) and normalised to 
OD595 readings of MTT experiments performed in parallel.
Real-time bioluminescence imaging
For imaging, 5000 Per2-dLuc- or Bmal1-dLuc-expressing cells were seeded in white 96-well plates with
clear bottom. The next day cells were synchronized with Dexamethasone (Sigma) for 2 hours, following 
which media was replaced with Leibovitz L-15 (Thermofisher) containing 10 % FCS and 150 µg/ml D-
Luciferin (Promega). Luciferase activity was measured using the IVIS Lumina II (PerkinElmer). Images
were collected at intervals of 60 min, with 10 min exposure duration, for up to 4 days. Images were
acquired using Living Image 3.2 Acquisition software (PerkinElmer), and analysed using Time Series 
Analysis 6.3 software (Expert Soft Tech.). Phase, period and amplitude were determined using





   
    
    
      
    
   
Statistical analysis
Statistical analyses were performed using Microsoft excel, where the student t-test was performed to
assess differences in sample means and a p value of < 0.05 was considered statistically significant. For
analysis of continuous luminometer readings, Time Series Analysis 6.3 software (Expert Soft Tech.) was
used. Period was calculated using the Jenkin and Watts autoperiodogram test and cosinor curves






       
   
     
       
     
    
      
 
    
      
    
     
   




      
        
 
  
      
  
Results
Circadian clock gene expression is downregulated in cervical and oesophageal cancer patient tissue
A microarray study we previously conducted, comparing the gene expression profiles of cervical tumour
tissue and normal epithelial tissue from cervical cancer patients and healthy controls, identified the
circadian clock gene, Period 2 (Per2), as one of the most significantly differentially expressed genes in
cervical cancer and normal cervical tissue 23,24. Its expression was amongst the ten most significantly
downregulated genes in cancer compared to normal (*p < 0.0005) (Suppl. fig. 1A). This downregulation
of Per2 suggests that the circadian clock is altered in cervical cancer. Data-mining of the Oncomine gene
expression database, a platform aimed at facilitating discovery from genome-wide expression analyses
25, confirmed downregulation of Per2 in cervical cancer tissue, and revealed significant downregulation
of other core circadian clock genes, Clock, Bmal1, Per1, Cry1, Rev-erbα and RORα in high grade
squamous intraepithelial lesion (HSIL) and/or cervical cancer tissue specimens compared to normal
cervical epithelium, using data derived from two independent studies 26,27 (Fig. 1A). The downregulation
of circadian clock genes in HSIL tissues suggests that deregulation of circadian clock gene expression
occurs as an early rather than late event in disease progression (Fig. 1Aii). Similarly, circadian clock gene
expression analysed using other valuable resources of gene expression data, The Cancer Genome Atlas 
(TCGA) and The Genotype Tissue Expression (GTEx) project, after removal of study-specific biases 28, 
revealed significant downregulation of several circadian clock genes in cervical tumour tissue compared
to normal (Suppl. fig. 2A). Bmal1 and Clock constitute the positive arm of the molecular circadian clock,
and Per and Cry genes the negative arm. RORα and Rev-erbα positively and negatively regulate
expression of Bmal1, respectively. In all datasets, positive and negative circadian clock genes were
downregulated. To show that there was not global downregulation of all genes using data derived from
TCGA and GTEx studies, expression of Ki67 and p16 was evaluated, and both were found to be at





   
        
     
     
   
    
           
   
    
   




   
   
 
    
     
 
    
  
Due to the observed downregulation of multiple members of the circadian clock gene family in cervical
cancer tissue, circadian clock gene expression in oesophageal cancer patient tissue was next 
investigated by Oncomine-data mining, to determine whether this effect was specific to cervical cancer
or a more general phenotype of cancer cells. Similar to the results obtained for cervical cancer, multiple
circadian clock genes were found to be downregulated in oesophageal squamous cell carcinoma (OSCC)
tumour tissue compared to matched normal epithelium in two independent datasets 29,30, including
Clock, Per1, Per2, Per3, Cry1, Cry2, Rev-erbα and RORα genes (Fig. 1B). Circadian clock gene expression
was similarly found to be downregulated in oesophageal tumour tissue compared to normal
oesophageal epithelium, using data obtained from TCGA and GTEx project resources (Suppl. fig. 2C).
Again, expression of Ki67 was found to be at increased levels in the tumour tissue compared to normal,
as well as expression of a suggested biomarker for oesophageal cancer, Karyopherin alpha 2 (Kpnα2) 31 
(Suppl. fig. 2D).
Having access to oesophageal tumour tissue and matched normal epithelial tissue from patients with
oesophageal squamous cell carcinoma, we next performed real-time RT-PCR analysis using RNA isolated 
from frozen tissue specimens, to independently validate Oncomine and TCGA data findings in a South
African subset of patients. Real-time RT-PCR analysis revealed significant downregulation of Clock, Per1, 
Per2, Per3, Cry1, Cry2, Rev-erbα and RORα in oesophageal cancer tissue compared to normal 
oesophageal epithelium counterparts (Fig. 1C). Interestingly, Bmal1 expression was unchanged in both
Oncomine and real-time RT-PCR analyses. To address possible correlations between gene expression 
changes, pair-wise correlation analyses were performed using the RT-PCR data (for genes which showed




   
     
  
 
     
  
 
   
 
  
    
     
    
 
   
       
 
  
     
  
   
     
      
fold changes in cancer vs normal specimens. Strong positive correlations were identified between
several circadian clock genes, where downregulation of one gene significantly correlated with
downregulation of another (Suppl. table 1). 
These results show that collective downregulation of multiple circadian clock genes associates with
cervical and oesophageal tumour development.
Expression of circadian clock gene family members is dysregulated in transformed and cancer cell lines
Since circadian clock genes showed deregulated expression in patient tumour tissue, expression levels 
were next measured in cells grown in culture. The WI38 and SVWI38 cell lines are a useful pair in which
to compare gene expression levels, as the SVWI38 cell line is an SV40 large T antigen (T-Ag) transformed 
derivative of the WI38 normal human fibroblast cells, hence any differences in gene expression
observed can be attributed to the process of cellular transformation rather than heterogeneity between
cell lines. As cells in long-term culture have been removed from the entraining influence of the SCN, the 
master clock in the brain, their circadian clock oscillators become out of phase with each other and
require synchronisation for circadian clock gene expression to become rhythmic. Thus, to more
accurately compare circadian clock gene expression patterns between cell lines, cells were
synchronised, by treatment with the glucocorticoid analogue Dexamethasone, for 2 hours, which is 
known to be sufficient to synchronise the circadian clock of cultured cells, and circadian clock gene
expression monitored immediately following synchronization. Interestingly, real-time RT-PCR analyses
revealed significant downregulation of all the circadian clock genes in the transformed compared to
normal WI38 cells (Fig. 2A), apart from Rev-erbβ and RORβ which displayed unchanged expression




     
 
    
       
  
     
   
 
  
   
    
 
   
     
      
  
    
       
     
        
   
    
 
  
outside of lymphoid and skeletal muscle origin (Human Protein Atlas). Synchronization itself did not
significantly alter circadian clock gene expression patterns from that observed in unsynchronised cells, 
besides Per1 expression which was upregulated after synchronization (data not shown). This is 
consistent with the reported effect of Dexamethasone in inducing Per1 expression 32,33. Per1 expression 
was thus not included in subsequent analyses, as its levels were not representative of endogenous Per1. 
The downregulation of circadian clock genes in transformed cells suggests that transformation induces a 
global downregulation and repression of the circadian clock machinery.
Circadian clock gene expression levels were next measured in a panel of normal and cancer cell lines by
real-time RT-PCR, immediately after synchronisation of cells for 2 hours with Dexamethasone. ARPE-19
normal primary epithelial cells were used as the representative normal cell line, with immortalised
hTERT-RPE-1 cells representative of an immortalised cell line, and HeLa, CaSki and ME180, alongside 
WHCO1, WHCO5 and KYSE30, representative of cervical cancer cell lines and oesophageal cancer cell
lines, respectively. Clock, Bmal1, Cry1 and RORα showed significantly decreased expression in nearly all
the cancer cell lines compared to normal (Fig. 2B). Expression of Per2 was decreased in two of the three
cervical cancer cell lines but increased in the oesophageal cancer cell lines. Interestingly, the negative
regulator Rev-erbα was expressed at increased levels in the cancer cell lines compared to normal, 
contrary to the positive regulator RORα (Fig. 2B). Cry2 and Per3 expression was largely unchanged in the
cancer cell lines compared to normal, consistent with the cervical cancer patient data, as well as
expression of Rev-erbβ and RORβ (with RORƴ again difficult to detect) (Suppl. fig. 3B). Immortalised
hTERT-RPE-1 cells similarly showed reduced expression of Clock, Bmal1, Cry1 and RORα, with Rev-erbα
at increased levels. Overall, these results reveal deregulation of several circadian clock genes in cancer
cell lines compared to normal and suggest that the process of cell immortalization itself might be 





   
       
       
    
   
   
   
      
     
    
        
    
   
     
        
      
     




At the protein level, protein was harvested from cells immediately following synchronisation with
Dexamethasone, and Clock, Cry1, Rev-erbα and RORα were found to have decreased expression levels in 
transformed SVI38 cells compared to normal, with Cry1 barely detected in the transformed cells (Fig.
2C). Per2, on the other hand, was present at increased levels in the transformed cells compared to
normal, and a dominant upper band was present likely indicative of post-translationally modified Per2.
There is extensive post-translational regulation of circadian clock genes that occurs in the circadian clock 
pathway, including ubiquitination, phosphorylation, glycosylation, acetylation and sumoylation, amongst
others 1, and SV40 T-Ag-induced transformation appears to alter post-translational control of Per2. In
the cancer cell lines, Clock, Cry1, Rev-erbα and RORα were found at decreased levels in most of the
cancer cell lines compared to normal, while Bmal1 levels were largely unchanged and Per2 found at
elevated levels in most of the cancer cell lines compared to normal (Fig. 2D). These results largely
support the mRNA findings, with certain exceptions, and highlight the fact that mRNA and protein levels
do not always correlate, as demonstrated in previous studies 34,35 .
Together, these results reveal a significant downregulation or deregulation of circadian clock gene family
members, particularly Clock, Cry1and RORα in transformed and cancer cell lines at the mRNA and
protein levels, consistent with findings using patient tumour tissue. These differences in expression
between cell lines were evident not only immediately following synchronization but also at 12 and 24
hours post-synchronisation (Suppl. fig. 4). Their altered expression in cancer cells suggests these genes
might be important players in mediating cancer biology. 




     
      
   
     
      
    
    
       
    
 
     
     
     
      
        
     
   
     
    
  
  
    
  
 
Previous reports describe hypermethylation of circadian clock gene promoters in breast cancer and
ovarian cancer cells 36,37. Thus, to investigate whether methylation might be contributing to circadian
clock gene downregulation in cervical and oesophageal cancer cells, cells were treated with the
methylation inhibitor, 5-aza-2-deoxycytidine (5aza-2-dc) and circadian clock gene expression
determined. Cells were treated daily for 3 days, whereafter circadian clock gene expression was
monitored by real-time RT-PCR. Results showed that circadian clock genes, Cry1 and RORα, were
consistently upregulated after treatment with 5aza-2dc, in all the cancer cell lines tested, and Clock was
upregulated in two of the three cancer cell lines (Fig. 3A, B, C). Per2 expression was increased in HeLa
cells only (Fig. 3D), while Bmal1 and Rev-erbα expression was unchanged in response to 5-aza-2-dc 
treatment (data not shown). Treatment of normal ARPE-19 cells did not result in upregulation of
circadian clock genes but rather resulted in decreased expression of circadian clock genes, suggesting
that the effect of methylation in downregulating circadian clock gene expression is cancer-specific (Fig. 
3A-D). At the protein level, increased expression of Clock, RORα and Per2 (modified and unmodified
forms) was observed in representative HeLa cells after methylation inhibition with 5-aza-2-dc (Fig. 3E). 
Cry1 protein levels were marginally increased but difficult to examine due to their low levels of
expression in cancer cells (Fig. 3E). In contrast, ARPE19 non-cancer cells did not display increased levels
of Clock, RORα or Cry1 protein after 5-aza-2-deoxycytidine treatment, and in fact levels were decreased 
after treatment, in line with the mRNA findings. Per2 protein, on the other hand, was present at
increased levels after 5-aza-2-deoxycytidine treatment of ARPE19 cells, as were levels of its modified
form, suggesting that the Per2 protein is regulated by methylation in both normal and cancer cells. The 
unchanged Per2 mRNA levels in ARPE19 cells upon 5-aza-2-deoxycytidine treatment (Fig. 3D) suggest
that this effect on Per2 protein levels is indirect, for example via its stabilization in response to the 






       
     
    
    
     
     
    
  
     
     
    
  
 
    
      
       
          
     
  
    
 
Since cancer cells displayed increased expression of Clock, RORα, Cry1, and Per2 at the mRNA/protein 
level in response to methylation inhibition with 5-aza-2-deoxycytidine, the methylation status of these 
genes was next investigated in order to determine whether there was direct methylation of their
promoter regions. CpG island prediction software (Methprimer) was used and CpG islands were
identified in the 5’ DNA regulatory sequences of Clock, RORα, Cry1 and Per2 genes (predominantly in the
region -1000 to +1000, where the transcription start site is +1) (Suppl. fig. 5). Methylation-specific PCR
was next performed, where primers were designed to bind CpG-rich sites. Two sets of primers were
designed for each gene to discriminate between methylated and unmethylated DNA. Cell line genomic 
DNA was bisulfite converted to allow for the conversion of all unmethylated cytosines to uracil, and
amplification carried out using both primer sets. CpG methylase (SssI)-treated bisulfite-converted HeLa 
and ME180 genomic DNA served as positive controls for the methylation-specific primers (as CpG
methylase methylates all cytosines within CG dinucleotides) and PCR analysis followed by gel
electrophoresis revealed that methylation-specific primers positively amplified CpG methylase-treated
DNA, as expected (Fig. 3F, first two panels). 
For analysis of the methylation status of each cell line, methylation-specific PCR revealed that Clock,
RORα and Cry1 genes were all methylated to varying extents in their 5’ upstream regulatory regions in
the CpG-rich regions examined (Fig. 3F). Interestingly, Per2 was not methylated in any of the cell lines
tested (Fig. 3F). While the Cry1 gene promoter was fully methylated in all five cancer cell lines (no bands
were detected using primers designed to amplify unmethylated DNA), Clock and RORα genes were
found to be partially methylated, where DNA was amplified using both unmethylated and methylated 





     
    
  
      
       
   
      
   
     
        
 
    
 
  
    
  
   
    
     
 
     
 
To further investigate whether methylation was responsible for the decreased expression of circadian
clock genes in cancer cells, it was determined whether treatment with 5-aza-2-deoxycytidine could
reduce methylation of Clock, RORα and Cry1 circadian clock gene promoters, thereby contributing to
their reactivated expression in response to 5-aza-2-deoxycytidine treatment. Cells were treated with 5-
aza-2-deoxycytidine for three days and DNA bisulfite converted before real-time methylation-specific
PCR was performed. Positive amplification of Clock, RORα and Cry1 was clearly detected in untreated
cancer cells using methylation-specific primers, which decreased after treatment with varying 
concentrations of 5-aza-2-deoxycytidine. Methylation of Clock, RORα and Cry1 gene promoters was also 
investigated in ARPE19 cells but it was found that ARPE19 cells displayed substantially reduced
methylation of Clock, RORα and Cry1 gene promoters compared to cancer cells. There were, however,
low levels of promoter methylation detected in these cells, which became apparent as the number of
amplification cycles increased (Fig. 3G). Interestingly, however, unlike in the cancer cells, methylation of
Clock, RORα and Cry1 gene promoters was not reduced upon treatment of ARPE19 cells with 5-aza-2-
deoxycytidine. 
Together, these results demonstrate that cancer cells lines exhibit low levels of Clock, Cry1 and RORα
gene expression due, at least in part, to hypermethylation of CpG islands in their promoter regions. 
While the Per2 promoter was not found to be methylated, the increased expression of Per2 in response
to methylation inhibition could be an indirect effect, and possibly due to the regulation of Per2
expression/stability by Clock, Cry1 and RORα gene family members. 
Constitutive expression of Clock and Per2 and activation of Rev-erba and RORa results in suppressed




   
       
   
    
    
    
    
      
     
     
   
 
    
     
   
        
  
     
  
    
    
    
       
        
As cervical and oesophageal cancer patient tissue and cell lines displayed reduced circadian clock gene 
expression, it was next investigated whether there was a link between downregulated circadian clock 
gene expression and cancer biology. Circadian clock genes were overexpressed in cervical and
oesophageal cancer cells, as well as in non-cancer ARPE19 cells, using circadian clock gene expression
plasmids, and cell proliferation monitored using the MTT assay. HeLa, CaSki, ME180 and WHCO5 cancer 
cell lines all displayed significantly reduced proliferation after Clock and Per2 overexpression, compared
to cells transfected with the corresponding empty vector controls (Fig. 4A, B). ARPE19 cell proliferation,
on the other hand, was unaffected by Clock or Per2 overexpression. Bmal1 and Cry1 overexpression did
not significantly affect cell proliferation in any of the cell lines (Fig. 4C, D). Western blot analysis
confirmed successful overexpression of all circadian clock genes (Fig. 4E). Interestingly, the more slowly 
migrating modified form of Per2 was again observed in the Per2 overexpressing cell lysates.
To explore the effect of enhancing Rev-erbα and RORα activity on cell proliferation, cells were treated
with Rev-erbα and RORα agonists, SR9011 38 and SR1078 39, respectively. These agonists have been
reported to specifically enhance Rev-erbα and RORα receptor function. Cells were treated with agonists
for 72 hours and MTT analysis revealed that treatment with both agonists resulted in significantly
reduced cancer cell proliferation, in a dose-dependent manner, in all cancer cell lines, with the effects of 
the RORα agonist SR1078 being more potent than the Rev-erbα agonist SR9011 at equivalent
concentrations (Fig. 4F, G). Interestingly, normal epithelial ARPE19 cells were significantly less affected 
by treatment, with SR9011 having no inhibitory effect on cell proliferation, and SR1078 only able to 
reduce cell proliferation at the highest concentration tested (lower concentrations of SR1078 in fact
enhanced ARPE19 cell proliferation) (Fig. 4F, G). Proliferation assays performed on WI38 and SVWI38
cells treated with agonists too revealed that SR9011 was more potent at killing transformed cells





       
   
 
   
    
     
     
   
  
 
     




     
    
     
       
   
    
Trypan blue assays verified results in representative cancer cell lines, revealing a significantly reduced
number of cancer cells upon SR9011 and SR1078 treatment, and a significantly increased number of 
dead cells, signifying that Rev-erbα and RORα activation results in the induction of cancer cell death (Fig.
4H, I).
To corroborate the induction of cell death upon Rev-erbβ and RORα agonist treatment, Caspase-3/7 
activity was measured in cancer cells after treatment with SR9011 and SR1078. Caspase-glo-3/7 activity 
was significantly induced in HeLa, ME180 and WHCO5 cells upon treatment with agonists, confirming
the induction of apoptosis in response to Rev-erbβ and RORα activation (Fig. 4J). Increased cleavage of 
Parp-1 protein was also observed in cancer cells upon treatment, again confirming apoptosis as the 
mechanism of cell death (Fig. 4K). 
Together, these results show that the overexpression/activation of specific circadian clock gene family
members, Per2, Clock, RORα and Rev-erbα, acts to suppress the proliferation and viability of cancer cells, 
resulting in cancer cell death via apoptosis, while having a lesser effect on non-cancer cells.
Rhythmic activity of circadian clock genes in cancer cells
The functional impact of circadian clock gene downregulation in cancer cells was further investigated by
measuring the circadian rhythms of cervical cancer and oesophageal cancer cells. Luminescence was
measured in cervical and oesophageal cancer cells harbouring a destabilised luciferase (dLuc) gene
under the control of the Per2 or Bmal1 promoter. These stable Per2-dLuc or Bmal1-dLuc cells were
generated using the Tol2 transposon system 16. Real-time monitoring of luciferase activity revealed 




   
      
  
       
    
     
  
 
    
   
    
   
       
 
     
   
  
 
     
 
    
  
   
was significantly enhanced upon synchronisation with Dexamethasone, where robust rhythmic 
expression of Per2-dLuc was observed (Fig. 5A). Data was detrended and the best corresponding cosinor 
curve fit, whereafter the period could be calculated using the Jenkins and Watts autoperiodogram test.
A period of 26.0 ± 0.83 hr and 25.9 ± 0.84 was determined for HeLa and WHCO5 cell lines, respectively,
close to the intrinsic 24 hour timing of normal cells. Bmal1-dLuc activity showed an inverse pattern of
oscillation to Per2-dLuc activity and was antiphase, as is expected of positive and negative circadian
clock regulators (Fig. 5B). Plots of peak activity are shown in Fig. 5C. 
Real-time monitoring of luciferase activity in additional cancer cell lines revealed distinct circadian
oscillation of Per2-driven bioluminescence in all the cervical cancer (Fig. 5Di) and oesophageal cancer 
(Fig 5Dii) cell lines tested. Cosinor curves fitted to each dataset are shown, where the population-mean
cosinor method was used (using TSA-Cosinor software). While amplitude varied between cell lines, this
could be due to variability in total luminescence emitted from cells (due to different transfection
efficiencies of cell lines and varying cell confluency), rather than heterogeneity between cell lines.
Circadian oscillations are better compared by measuring the circadian phase and period. Interestingly,
all cancer cells displayed a period of between 24 and 27 hours, and similar acrophase (peak in Per2-dLuc
activity), except for the metastatic cervical cancer cell line, CaSki, which displayed a significantly delayed
phase and increased period, compared to the non-metastatic cervical cancer, HeLa and ME180, and
oesophageal cancer, WHCO5 and KYSE30 cells (Fig 5E). This is consistent with previous reports 
describing a delayed circadian phase and increased circadian period in metastatic cancer cell lines 40. As 
a control the circadian rhythm of human osteosarcoma cells, U2OS, was analysed, as this is a widely
used in vitro model to study properties of the mammalian circadian clock 41. Importantly, similar 




      
 
 
     
     
      
     
     
     
     
 
     
       
      
  
       
  
        
        
   
    
   
    
(Fig. 5E). Together, these results reveal that despite dysregulated circadian clock gene expression,
cervical cancer and oesophageal cancer cell lines maintain functional circadian oscillations. Discussion
This study identifies suppressed expression of circadian clock gene family members in cervical and
oesophageal tumour tissue, compared to normal epithelium, as well as in cultured cervical and 
oesophageal cancer cell lines, compared to normal epithelial cells. Furthermore, it reveals that despite
dysregulated gene expression, cervical cancer and oesophageal cancer cells display overt circadian
rhythms, based on their oscillating profiles of Per2 and Bmal1 promoter activity after synchronization. In 
addition, it shows that perturbation of the circadian clock pathway, via overexpression of Clock and Per2
genes, or activation of RORα and Rev-erbα using small molecules, inhibits cancer cell biology (Figure 6).
Circadian clock gene expression has been reported to be altered in various cancer types, where circadian
clock genes have been reported to be downregulated in breast cancer 9, colorectal cancer 42, tongue
squamous cell carcinoma 43 and gastric cancer 44, amongst others. There are multiple mechanisms by
which dysregulated circadian clock gene expression may occur, for example, via the action of oncogenes 
or cancer/testis antigens. Relogio et al. (2014) showed how Ras perturbation can disrupt the circadian
clock and revealed differential expression of core clock genes in normal and Ras-transformed cells 40, 
while Michael et al. (2015) showed how the cancer/testis antigen Pasd1 represses Bmal1:Clock activity
in cancer cells 45. Hypermethylation of the promoter regions of circadian clock genes has also been
described, acting to downregulate circadian clock gene expression in breast cancer tissue 36 and ovarian 
cancer cells 46. Our study shows decreased expression of core circadian clock genes in cervical and
oesophageal cancer cells, and reveals that methylation plays a direct role in mediating downregulated 




    
  




     
    
  
       
 
    
     







      
  
 
factors such as oncogenes and cancer/testis antigens in further controlling circadian clock gene 
expression remains to be determined.
It was noted in our study that the mRNA and protein profiles of circadian clock genes did not always 
correlate. Shu et al (2004) describe how circadian clock gene oscillations are controlled by four-step-
expression, where transcription, translation, degradation of mRNA, and degradation of protein are all 
vital in controlling gene expression 47. It is possible that in the cancer cell lines in our study, differing
protein/mRNA half-life in different cell lines may lead to the lack of correlation between mRNA and
protein. Furthermore, a modified, more slowly migrating form of Per2 protein was observed in 
transformed SVWI38 cells (Fig. 2C), HeLa and ARPE19 cells treated with methylation inhibitor 5-aza-2-
deoxycytidine (Fig. 3E), and in cells in which Per2 was overexpressed (Fig. 4E). Miyazaki et al. (2004)
reported that the size of Per2 fluctuates after synchronization of WI38 cells (it increases in size up to 
approximately 200 kDa: the size of the modified Per2 protein in our study) and showed that this is due
to phosphorylation of Per2 by CKI (casein kinase I) proteins 48. It has also been reported by Camacho et
al (2001) that CKI proteins can phosphorylate overexpressed Per1 and Per2 in vitro and induce an
increase in the apparent molecular size of Per proteins 49. Future work will be required to investigate
why increased phosphorylation of Per2 might be occurring under the various cellular conditions 
observed.
Chang and Lai (2019) recently showed that circadian clock genes that confer tumour suppressing effects
in one cancer type can play an opposing role and exhibit tumour-promoting effects in another cancer
type 13. We show that in cervical and oesophageal tumour cells Per2, Clock, RORα and Rev-erbα display
tumour-inhibiting properties, as their overexpression/activation (in cells displaying low levels of 




    
   
  
     
    
  
     
   
  
    
    
   
   
       
   
    
   
 
 
     
  
    
   
 
cell death upon activation of RORα and Rev-erbα, normal cells respond differently. ARPE19 and WI38
non-cancer cells are less sensitive to SR9011 compared to cancer and transformed cells, where
concentrations that result in cancer cell death do not inhibit ARPE19 or WI38 cell proliferation. In
addition, APRE19 cell proliferation is only inhibited at SR1078 concentrations of >30 µM, although WI38
cells are sensitive to lower concentrations of SR1078. These results suggest that Per2, Clock, RORα and
Rev-erbα circadian clock genes might have potential as druggable targets, whereby their activation could
have therapeutic potential. Rev-erbα agonists have been suggested to be potential treatment options
for different types of cancer 50. The activation of Rev-erbα has been proven advantageous in that it 
appears to be non-damaging to healthy tissue, and can act to rid the tumour of not only actively
proliferating cells, but also oncogene-induced senescent cells, which play a role in mediating 
chemotherapy resistance and relapse 50. It has been proposed that Rev-erbα activation suppresses
expression of Cyclin A in breast cancer cells, contributing to cell cycle arrest 51. The activation of RORα
has been shown to induce p53 expression and activate cell death in HepG2 cells 39. Our results support
the use of Rev-erbα and RORα agonists, SR9011 and SR1078, against cervical and oesophageal cancers.
Further work investigating the use of these agonists in treating these types of cancer is required.
Particularly, further studies are needed to address whether the overexpression/activation of circadian
clock components leads to the observed anti-tumoural effects via interfering with the circadian rhythm
of cancer cells, or via alternate pathways. 
Our study also examined the circadian oscillatory profiles of cervical and oesophageal cancer cells.
Literature suggests that the circadian rhythm is often suppressed in cancer cells. Breast cancer cells have 
been shown to display arrhythmic patterns of circadian clock gene expression, and while serum shock 
can induce oscillation of some circadian clock genes, the amplitude is greatly reduced compared to




    
    
     
   
  
 
   
      
       
   
       
   
  
      
 
 
    
    
 
   
  
   
 
malignancy MCF7 cells do display circadian oscillations of Per2 and Bmal1, while high-grade MDA-MB-
231 cells do not 56. In tumour tissue in vivo, it has been previously shown that Glasgow osteosarcoma
and pancreatic adenocarcinoma tissues display absent, or very weak rhythmic profiles of circadian clock
genes 7,57. Interestingly, Relogio et al. (2014) describe how colon cancer cell lines show a rich variety of
circadian phenotypes, where some showed strong and others weak to no-oscillation phenotypes (these
authors classify a strong oscillator as a cell line with a clear circadian period and amplitude variation of 
at least 20 %) 40. Moreover, they identified a list of genes able to discriminate between weak and strong
oscillator cell lines by transcriptome analysis, and the roles of these genes in both circadian clock and
oncogenic pathways suggests these pathways are strongly connected. Our results show that the cervical
and oesophageal cancer cells examined display strong oscillating phenotypes, despite deregulated 
circadian clock gene expression. There was little difference in the period and acrophase described in the
different cell lines, besides the CaSki metastatic cancer cell line having a significantly increased period
and delayed phase compared to the other cells. Together, these findings reinforce that cancer cells can 
maintain rhythmic circadian profiles and suggests that these rhythmic profiles might be contributing to
cancer biology.  
It has been shown that the circadian rhythm of clock genes becomes markedly impaired in senescent or
“aging” cells, and that this can be reversed by telomerase reconstitution 58. As cancer cells display
increased telomerase activity, this could in part explain the overt circadian rhythms observed in the 
cancer cell lines used in our study. Interestingly, it has also been shown that telomerase mRNA 
expression and activity exhibits endogenous circadian rhythmicity and is under the control of the Clock-





    
 
    




In conclusion, the disruption of circadian clock components in cancer, or “circadian reprogramming” can
be a critical player in tumourigenesis, while maintenance of circadian rhythms might also act to uphold
cancer-related processes. Chang and Lai (2019) demonstrate that circadian reprogramming of tumour
genomes plays an important role in influencing disease progression and patient outcomes 13. Ongoing
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Figure 1. Expression of circadian clock genes in patient tumour tissue. A. Levels of circadian clock gene
expression in normal and cervical cancer and/or HSIL tissue specimens, based on OncomineTM analysis, 
using data obtained from (i) Scotto et al. (2008) (20 normal squamous epithelial samples and 20 primary 
tumours) and (ii) Zhai et al. (2007) (10 normal cervix samples, 7 HSILs and 21 invasive cervical SCCs). B. 
Levels of circadian clock gene expression in oesophageal cancer and matched normal tissue specimens, 
based on OncomineTM analysis, using data obtained from (i) Hu et al. (2010) (n = 17) and (ii) Su et al.
(2011) (n = 53). C. Real-time RT-PCR analysis showing circadian clock gene expression levels in 
oesophageal cancer tissue and matched normal oesophageal epithelium from South African OSCC
patients (n = 24). *p<0.05.
Figure 2. Expression of circadian clock genes in cultured cell lines. A. Real-time RT-PCR analysis showing 
circadian clock gene expression levels in normal WI38 cells and matched transformed SVWI38 cells, after
synchronisation. B. Real-time RT-PCR analysis showing circadian clock gene expression levels in normal
ARPE19 epithelial cells, immortalized hTERT-RPE-1 epithelial cells and cervical cancer (HeLa, CaSki,
ME180) and oesophageal cancer (WHCO1, WHCO5, KYSE30) cells (*p<0.05). C. Western blot analysis
showing circadian clock protein levels in WI38 and SVWI38 cells. p38 was used as a control for protein
loading. D. Western blot analysis showing circadian clock protein levels in ARPE19, hTERT-RPE-1 and





    
        
    
    
    
    
        
  
  
     




   
       
   
     
    
    
  
    
      
    
Figure 3. Methylation analysis of circadian clock genes in cancer and non-cancer cells. A-D. Cervical
cancer (HeLa, CaSki, ME180) and normal epithelial (ARPE19) cells were treated with 2.5, 5 or 10 µM 5-
aza-2-deoxycytidine (5-aza-2-dc) for 72 hours and gene expression monitored by real-time RT-PCR.
Experiments were performed in triplicate and results are shown as the mean ± SEM (*p<0.05). E. 
Western blot analysis showing protein levels of circadian clock genes after methylation inhibition in 
HeLa cells and ARPE19 cells with 5-aza-2-dc for 72 hours. F. Methylation-specific PCR analysis of Clock,
RORα, Cry1 and Per2 genes. DNA was bisulfite-modified, PCR amplified and electrophoresed on 1.5 %
agarose gels. SssI-treated DNA (bisulfite-converted) was used as a positive control for methylation-
specific primers. U and M indicate methylation-specific PCR using unmethylation-specific and 
methylation-specific primer sets, respectively. G. Real-time methylation-specific PCR analysis of Clock, 
RORα and Cry1 genes after treatment of cells with 5-aza-2-deoxycytidine for 72 hours. CT values reflect 
the number of cycles required for the fluorescent signal to cross a threshold, where ut denotes
undetected fluorescent signal.
Figure 4. Effect of circadian clock gene overexpression/activation on cell proliferation. A-D. Cell
proliferation was measured 96 hours after circadian clock gene overexpression using the MTT assay. E.
Western blot analysis showing protein overexpression with the respective circadian clock gene 
overexpression constructs. p38 was used as a control for protein loading. F. Cell proliferation after
treatment of cells with Rev-erbα and RORα agonists, SR9011 and SR1078, for 72 hours, measured using
the MTT assay. H, I. Number of live and dead cells after treatment of ME180 (i) and WHCO5 (ii) cells with
SR9011 (H) and SR1078 (I) for 72 hours, measured using the trypan blue assay. J. Caspase-3/7 activity
measured in cancer cells after treatment with SR9011 or SR1078 for 72 hours. Experiments were
performed in triplicate and results are shown as the mean ± SEM (* denotes significance relative to




     
  
 
   
    
      
       
   
     
   









    
   
    
 
in SR9011- or SR1078-treated cancer cells. p38 was used as a protein loading control. Cleaved Parp-1
was quantified using Image J and expressed relative to uncleaved Parp-1 and p38. 
Figure 5. Circadian oscillations of cancer cells. A. Real-time bioluminescence monitoring showing
oscillating Per2-dLuc activity in synchronized HeLa (i) and WHCO5 (ii) cells over time. B. Real-time
bioluminescence monitoring showing oscillating Bmal1-dLuc activity in synchronized HeLa (i) and
WHCO5 (ii) cells over time. C. Plots showing peak Per2-dLuc and Bmal1-dLuc activity in HeLa (i) and
WHCO5 (ii) cells. D. (i) Oscillating profiles of Per2-dLuc activity in HeLa (blue), CaSki (orange) and ME180 
(red) cervical cancer cells. Cosinor plots were generated using TSA-Cosinor software. (ii) Oscillating 
profiles of Per2-dLuc activity in WHCO5 (blue) and KYSE30 (red) oesophageal cancer cells over time. E. 
Plots showing acrophase of Per2-dLuc activity (i) and period values (ii) obtained from analysis of 
circadian oscillations of different cell lines, using TSA-Cosinor software. Data shown are averaged across
at least three independent experiments with four technical repeats in each; mean ± SEM are shown 
(*p<0.05).
Figure 6. Summary model. Under normal cellular conditions, the Clock/Bmal1 heterodimer binds E-
boxes present in the promoter regions of core clock-controlled genes (CCGs), including Per, Cry, ROR and 
Rev-erb, activating gene expression. Once translated, Per and Cry proteins dimerise and inhibit 
Clock/Bmal1 activity, repressing their own transcription. ROR and Rev-erb activate and inhibit 
expression of Bmal1, respectively. The result is oscillating patterns of circadian clock gene promoter
activity. In the cancer state, Clock, Cry1 and RORα promoters are hypermethylated, repressing Clock, 
Cry1 and RORα gene mRNA and protein expression, and impacting overall circadian clock gene mRNA 




        
    




circadian clock using ROR and Rev-erb agonists, SR1078 and SR9011, or overexpression of Per and Clock
genes, leads to cancer cell death, suggesting perturbation of the circadian clock pathway could be 
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200bp
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Amplicon size: 150 bp
Location: -1203 to -1054)
Clock-UM 
Amplicon size: 148 bp
Location: -1201 to -1054)
Forward: 5’- TTAGTAATCGGCGTCGTTTTCGGTC-3’ 55°C
Reverse: 5’- CGATACGCATACGACTTACCCCGTT-3’
Forward: 5’- AGTAATTGGTGTTGTTTTTGGTTGG-3’ 52°C
Reverse: 5’- CAATACACATACAACTTACCCCATT-3’
RORα-M Forward: 5’-GGCGGTTATAGGTGATTTCGAAGGC-3’ 55°C
Amplicon size: 124 bp Reverse: 5’-CGCGAACAAATAAATAACAACGACGAC-3’
Location: -292 to -169)
RORα-UM Forward: 5’-TGGTTATAGGTGATTTTGAAGGTGA-3’ 52°C
Amplicon size: 122 bp Reverse: 5’-CACAAACAAATAAATAACAACAACAAC-3’
Location: -290 to -169)
Cry1-M Forward: 5’-GGTAGTTTCGGGATCGGTTATCGG-3’ 55°C
Amplicon size: 122 bp Reverse: 5’-AAAATAAACCCCTATCGACGACGCT-3’
Location: +11 to +132)
Cry1-UM Forward: 5’-GGGTAGTTTTGGGATTGGTTATTGG-3’ 52°C
Amplicon size: 124 bp Reverse: 5’-AAAAATAAACCCCTATCAACAACACT-3’
Location: +10 to +133)
Per2-M Forward: 5’-GATTTTTCGGTTTGAAACGGCGTC-3’ 55°C
Amplicon size: 136 bp Reverse: 5’-GAAAATTCGAATCCCCAACCCTCG-3’
Location: +94 to +229)
Per2-UM Forward: 5’-TGTTGGATTTTTTGGTTTGAAATGGTGTT-3’ 52°C
Amplicon size: 141 bp Reverse: 5’-AAAAATTCAAATCCCCAACCCTCAAT-3’
Location: +89 to +229)
The locations indicated are relative to the transcriptional start site at +1. M: methylated-specific 
primers, UM: unmethylated-specific primers.
